Skip to main content

Eva Colas Ortega

I am principal researcher in the Group of Biomedical Research in Gynecology, where I lead the translational research group. My research interest is to provide solutions for unmet clinical needs in gynecology, mainly in endometrial cancer and endometriosis. We work on biomarker research to provide with innovative solutions and preclinical models to improve personalized medicine.

Institutions of which they are part

Head of group
Biomedical Research in Gynaecology
Vall Hebron Institut de Recerca

Eva Colas Ortega

Institutions of which they are part

Head of group
Biomedical Research in Gynaecology
Vall Hebron Institut de Recerca

I am principal researcher in the Group of Biomedical Research in Gynecology, where I lead the translational research group. My research interest is to provide solutions for unmet clinical needs in gynecology, mainly in endometrial cancer and endometriosis. We work on biomarker research to provide with innovative solutions and preclinical models to improve personalized medicine.

I am biologist by formation and fully dedicated to endometrial cancer research for the last 16 years. From 2017, I lead my own team in the Group of Biomedical Research in Gynecology (VHIR) and my research focus on the implementation of molecular diagnostics and personalized medicine in gynecology, mainly in endometrial cancer (EC) and endometriosis.
In my career I participated in the development of the first EC patient-derived murine models (PDX), and today, my group owns one of the largest PDX biobanks in Europe, which is used by us, partners and pharma to assess treatments for EC patients. Importantly, I have also grown as a scientist dedicated to biomarker research in gynecological fluids. I worked in the development of the first molecular kit to diagnose EC. Today, I am the European Coordinator of a multicenter study to develop a non-invasive diagnosis of EC (ERA PerMed), and am the founder of a spin-off (MiMARK Diagnostics S.L.) that aims to develop innovative solutions for women health.
As a summary, I have a total of 73 scientific articles with impact factor; 17 of them as senior author; and am inventor of 4 patents. My scientific and leadership capacity is proved by the supervision of 12 doctoral theses, 6 of which have already been defended, two of them awarded. I have participated in 32 competitive research projects, being 13 of them principal investigator, and I am actively participating in national (CIBERONC) and international (ENITEC) cancer networks.
I have been teaching in graduate and master studies for the last 7 years; and I have been on the Steering Committee of the Societat Catalana de Biologia for 10 years.

Projects

Desenvolupament d'una eina de diagnòstic no invasiva en el càncer d'endometri

IP: Antonio Gil Moreno
Collaborators: Eva Colas Ortega, Miriam Izquierdo Sans
Funding agency: Generalitat de Catalunya - Departament de Salut
Funding: 104111.51
Reference: SLT002/16/00315
Duration: 01/04/2017 - 28/09/2020

Unitat de Recerca Biomèdica i Oncologia Translacional (GRC)

IP: Jaume Reventós Puigjaner
Collaborators: José Placer Santos, Joan Morote Robles, Maria Asuncion Perez Benavente, Eva Colas Ortega, Berta Diaz Feijoo, Silvia Cabrera Diaz, Antonio Gil Moreno, Marina Rigau Resina, Jacques Planas Morin
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 50000
Reference: 2014 SGR 1330
Duration: 01/01/2014 - 31/12/2016

Desarrollo de algoritmos predictivos de riesgo de recidiva y respuesta a terapia en cáncer de endometrio

IP: Eva Colas Ortega
Collaborators: -
Funding agency: Fundació Santiago Dexeus Font
Funding: 6000
Reference: FSDF-2013-03
Duration: 31/01/2014 - 31/01/2016

ProstatePredict. Desarrollo de una prueba de pronóstico para predecir la probabilidad de enfermedad agresiva después de la cirugía

IP: Jaume Reventós Puigjaner
Collaborators: Eva Colas Ortega
Funding agency: Ministerio Economía, Industria y Competitividad
Funding: 150405
Reference: IPT-2012-1311-300000
Duration: 17/12/2012 - 30/04/2016

Related news

From 6th to 7th March, more than 60 European researchers have shared the advances in translational research in endometrial cancer

On January 24, a session was held to explain what these three-dimensional models are and what advantages they have, as well as to review some of their applications in research.

A team from Vall d'Hebron Research Institute (VHIR) and the Autonomous University of Barcelona (UAB) highlights the ERK5 protein as a key factor in the resistance to cancer drugs.

Related professionals

Alejandro  Henao  Paez

Alejandro Henao Paez

Physiology and Pathophysiology of the Digestive Tract
Read more
Amira Idrizovic

Amira Idrizovic

Predoctoral researcher
Childhood Cancer and Blood Disorders
Read more
Cristina Gamez Cenzano

Cristina Gamez Cenzano

Senior researcher
Molecular Medical Imaging
Read more
Camille Guillard Sirieix

Camille Guillard Sirieix

Research technician
Neurodegenerative Diseases
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.